UBS has reaffirmed its Buy rating on Madrigal Pharmaceuticals, setting a price target of $441, reflecting confidence in the company's potential in treating metabolic-associated steatohepatitis (MASH). Following strong fourth-quarter results, with revenues of $180 million and a gross margin of 96.54%, analysts remain optimistic about Madrigal's future, particularly with promising data from the Phase 3 MAESTRO-NAFLD-1 trial. The company holds a robust financial position, with cash and marketable securities totaling $931.3 million, and anticipates a potential European launch of its drug Rezdiffra in 2025, pending regulatory approval.